Cambridge Innovation Capital has launched a new £100 million Opportunity Fund – anchored by Aviva Investors and British Patient Capital – to invest in growing DeepTech and life science companies.

In February 2023, the BVCA brought out their latest set of Series A model investment documents (‘the Model Documents”).

Early in November 2024 Cambridge Angels held one of its externally sponsored dinners; this time on GenAI: “Land Grab or Bubble”. Held at Clare Hall in Cambridge, it brought together 30 prominent academics, investors and corporate leaders active in this space.

It’s the “biggest set of reforms to the pensions market in decades”, says finance minister Rachel Reeves

Cambridge University Health Partners (CUHP) is delighted to announce that Lord James O’Shaughnessy will take over from Laurel Powers-Freeling as the new Chair, starting at the beginning of next year.

Successful spinouts include Flusso, Riverlane, Phoremost, Horizon Discovery, Nyobolt and Psyomics.

More than $994 million has been raised by Cambridge technology companies in the past 12 months (to October 16, 2024) – helped by Pragmatic, Quantinuum and Raspberry Pi pulling in $731m between them.

A blurring vision to create the same level of innovation in the next 10 years as achieved in the whole last quarter-century promises to propel Cambridge and its hinterland to the peak of global technology transformation.

Early this week the Blair institute published a comprehensive and well researched report on reforming the UK’s capital markets. 

o2h discovery is pleased to announce the launch of o2h Biology Match Funding, a unique programme aimed at accelerating drug discovery research by offering to match fund 50% of the cost for biology research projects up to $65K/£50K in value. This initiative presents an exciting opportunity for biotechs of all sizes and pharma to achieve key scientific milestones, helping to advance their drug discovery programmes.